Advertisement
Advertisement

XERS

XERS logo

Xeris Biopharma Holdings, Inc. Common Stock

8.34
USD
Sponsored
-0.28
-3.31%
Jul 10, 15:40 UTC -4
Open

XERS Earnings Reports

Positive Surprise Ratio

XERS beat 18 of 32 last estimates.

56%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$92.10M
/
$0.00
Implied change from Q1 26 (Revenue/ EPS)
+10.79%
/
-100.00%
Implied change from Q2 25 (Revenue/ EPS)
+28.74%
/
-100.00%

Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue

On May 07, 2026, XERS reported earnings of 0.01 USD per share (EPS) for Q1 26, beating the estimate of 0.00 USD, resulting in a 217.65% surprise. Revenue reached 83.13 million, compared to an expected 81.59 million, with a 1.88% difference. The market reacted with a +4.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 92.10 million USD, implying an decrease of -100.00% EPS, and increase of 10.79% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Cybin Inc. Common Stock
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.91
Actual
-$1.16
Surprise
-27.08%
FAQ
For Q1 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of $0.01, beating estimates by 217.65%, and revenue of $83.13M, 1.88% above expectations.
The stock price moved up 4.08%, changed from $6.37 before the earnings release to $6.63 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 6 analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of -- and revenue of $92.10M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement